Items where Author is "Srivastava, Raghvendra M"

Article

Trivedi, Sumita and Srivastava, Raghvendra M and Concha-Benavente, Fernando and Garcia-Bates, Tatiana M and Li, Jing and Ferris, Robert L (2015) Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients. Journal for ImmunoTherapy of Cancer, 3 (S2).

Srivastava, Raghvendra M and Clump, David A and Ferris, Robert L (2015) Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model. Journal for ImmunoTherapy of Cancer, 3 (S2).

Kansy, Benjamin A and Srivastava, Raghvendra M and Jie, Hyun-Bae and Shayan, Gulidanna and Lei, Yu and Li, Jing and Gooding, William and Brandau, Sven and Lang, Stephan and Schmitt, Nicole and Freeman, Gordon J and Clump, David A and Ferris, Robert L (2015) Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model. Journal for ImmunoTherapy of Cancer, 3 (S2).

Concha-Benavente, Fernando and Srivastava, Raghvendra M and Kansy, Benjamin and Ferris, Robert L (2015) PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer. Journal for ImmunoTherapy of Cancer, 3 (S2).

Ferris, Robert L and Kansy, Benjamin A and Gibson, Sandra and Srivastava, Raghvendra M and Bryan, James and Hershberg, Robert M (2015) A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC). Journal for ImmunoTherapy of Cancer, 3 (Suppl ). P144 - P144. ISSN 2051-1426

Srivastava, Raghvendra M and Jie, Hyun-bae and Ferrone, Soldano and Ferris, Robert L (2013) STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients. Journal for ImmunoTherapy of Cancer, 1 (S1).